Tigecycline suppresses colon cancer stem cells and impairs tumor engraftment by targeting SNAI1-regulated epithelial-mesenchymal transition.
Autores: Ruiz-Malagón AJ, Rodríguez-Sojo MJ, García-García J, Ho-Plagaro A, García F, Vezza T, Redondo-Cerezo E, Griñán-Lisón C, Marchal JA, Rodríguez-Cabezas ME, Rodríguez-Nogales A, Gálvez J
09/2025 - Acta pharmacologica Sinica